ANIMATION

Apoptosis and BCL-2

Share this animation:

ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptopic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.

Share It:
Contact XVIVO

Client


Abbvie; Genentech

The XVIVO group exemplifies the attributes of indispensable partners for executing complex projects. They match unquestionable scientific knowledge with outstanding creative capacity and solid project management. They’ve been truly valuable teammates.

Account Supervisor, Ogilvy Healthworld
Share this animation: